SUBSCRIBE
SUBSCRIBE
News   Drug Development

Vertex Pharmaceuticals (MA) Hepatitis C Drug, Telaprevir Achieves 75% Cure Rate in Study

May 26, 2010 | 
1 min read
Reuters -- A hepatitis C treatment being developed by Vertex Pharmaceuticals Inc led to a 75 percent cure rate in a pivotal trial of previously untreated patients, the company said on Tuesday.
Clinical research Phase III
Vertex Pharmaceuticals
MORE ON THIS TOPIC
Crumpled paper balls fly into a miniature bucket, the concept of searching for new ideas
Lung cancer
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Class Failures
May 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.
Obesity
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
May 12, 2025
 · 
2 min read
 · 
Tristan Manalac
istock/ArtemisDiana
PARTNERED
Where AI Adds Real Value in Clinical Development
May 12, 2025
 · 
7 min read
 · 
BioSpace Insights
Drug Development
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
May 8, 2025
 · 
1 min read
 · 
Lori Ellis